FDA's December 2025 letter to Medinatura New Mexico records a firm acknowledging that its cleaning validation was not reflective of current operations after years of buying new equipment and adding new products. What the gap looks like from the inside — and what it asks of change control.
What happened
On 10 December 2025 the US FDA issued Warning Letter 320-26-27 (MARCS-CMS 716025) to Medinatura New Mexico, Inc. (FEI 1626962), a manufacturer of homeopathic drug products at 10421 Research Road SE, Albuquerque, New Mexico. The letter comes from CDER's Office of Manufacturing Quality and is signed by its Director, Francis Godwin; the named recipient is the firm's CEO, Mr. Clifford Clive. It follows an inspection from 19 to 23 May 2025 and assesses the firm's 6 June 2025 response to the Form FDA 483 as inadequate. Three CGMP violations are cited. Product and equipment identifiers are redacted in the public text as "(b)(4)".
The second violation, under 21 CFR 211.67(b), is the one that belongs in a cleaning-validation discussion. The Warning Letter identifies that the firm's cleaning validation programme for non-dedicated manufacturing equipment used for multiple drug products "is inadequate". Specifically, the programme does not include the equipment used in tablet manufacturing — Intermediate Bulk Container (IBC) tanks, (b)(4) tanks, product transfer hoses and (b)(4) hoses. The Warning Letter identifies a second gap in the same passage: the firm lacks equipment usage logs and cleaning documentation sufficient to show that the equipment is adequately cleaned and to prevent carry-over contamination from a prior batch during production campaigns.
The history is set out in the firm's own response, as quoted by FDA. Medinatura acknowledged "that the cleaning validation is not reflective of your current operations, because you continued to purchase new equipment and add new drug products to your operations," and stated that it recognised the cleaning validation needed a comprehensive revision.
FDA judged that response inadequate, for two stated reasons: insufficient detail about the revised cleaning validation and its associated procedures, and no risk assessment of the quality of distributed drugs that are potentially contaminated because of inadequate cleaning practices. Under a separate process-validation finding (21 CFR 211.100(a)), the letter also records that the firm acknowledged it had not been properly updating its process validations when new drug products and equipment are added, and that its last official validation study was completed in 2007, when the company was under different ownership.
What FDA asks for reads like a description of the gap itself: a comprehensive, independent retrospective assessment of cleaning effectiveness, covering the identity of residues, other equipment that may have been improperly cleaned, and whether cross-contaminated products may have been released — encompassing each piece of equipment used to manufacture more than one finished product; a CAPA plan built on that assessment, including a summary of vulnerabilities in the lifecycle management of equipment cleaning and improved ongoing verification that cleaning is actually executed; an improved cleaning validation programme with explicit worst-case identification and evaluation; a description of the steps the change management system must take before a new manufacturing equipment item or a new product is introduced; and updated SOPs for verification and validation of cleaning procedures.
Why it matters
Cleaning validation is a demonstration tied to a particular equipment train and product set. It is not self-updating. Anything the plant adds afterwards — an item of equipment, a new product, a different presentation on the same line — is a question about whether that demonstration still describes what the plant does. The Medinatura letter is a documented instance of the answer being no, acknowledged by the firm itself, and of the follow-up question FDA then asks: if the study no longer matches the operation, what does that mean for the batches already made and distributed?
The second half of the FDA request is the part that is easy to underestimate. Usage logs are not administrative decoration. Without a record of which product ran before which on a shared item, an assessment of carry-over cannot be scoped to defined batches. FDA asks the firm to identify equipment that may have been improperly cleaned and to assess whether cross-contaminated product was released, and that request presupposes records the letter says were not kept.
What is particularly interesting
The word "lifecycle" appears in the letter not as a slogan but as a description of the failure. FDA asks for "a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning" — the deficiency is framed as a management process that did not notice its own validation had gone stale, not as a single missed study.
The remediation list is also notable for what it does not do. FDA does not prescribe a MACO formula, a residue limit or a sampling technique. It asks for worst-case to be identified and evaluated — drugs of higher toxicity, higher potency, lower solubility in the cleaning solvent, drugs otherwise difficult to clean; hardest-to-clean swabbing locations; maximum hold times before cleaning — and leaves the firm to justify the choice. Concepts that overlap with health-based exposure limit thinking appear here as selection criteria; the letter does not request a particular PDE calculation. Likewise, the change-management request is about a step in a process, not about a specific document.
How such a gap can realistically develop
A plausible, unremarkable sequence looks like this. A firm grows by adding equipment and products incrementally, each addition small and individually defensible. The cleaning validation, meanwhile, is a defined study that covered a defined scope on a defined date. The only thing that connects the two is a change-control step that asks the cleaning question. If purchasing an IBC tank or adding a tablet presentation is handled as an engineering, facility or commercial event rather than as an event in the validated state, the question "does this change our worst case, our coverage, our hold times?" is simply never asked by anyone. Nothing looks wrong locally; the study is complete, approved and filed.
Ownership and staff change on top of that. The letter records a 2007-vintage study completed under different ownership — three changes of institutional knowledge ago. Without usage logs, even an organisation that later decides to re-examine its position cannot reconstruct which products shared which equipment. That is not a failure of intention; it is a failure of design in the documentation and change-control system, and the letter's remedy is aimed exactly there.
Questions worth asking in our own programme
- For each non-dedicated equipment item, is there a current list of the products it carries, and does the cleaning validation cover that list as it stands today — not as it stood when the study was approved?
- When we buy equipment or add a product, which document forces the question "does this change our validated cleaning state?", and does QA sign that decision before the item enters production?
- Could we reconstruct, from records, which product ran before which on each shared item during the last campaign window? If not, what would an investigation actually be able to scope?
- Does our periodic review of cleaning re-test the worst-case selection after products and equipment change, or does it mainly confirm that existing procedures were followed?
- Are maximum hold times before cleaning defined against the equipment train and product mix we run now?
- Where our records show a new product or equipment item added since the last cleaning study, is there a written, dated technical rationale for why the study still applies?
Wider context
The letter's framing is consistent with the expectations FDA set out in its 2011 guidance Process Validation: General Principles and Practices, which the letter itself cites under the process-validation finding, and with the general principle that a validated state is maintained, not achieved once. Readers working under EU GMP will recognise the worst-case and hold-time elements from Annex 15 and the health-based exposure limit discussion in the EMA's shared-facility guideline; the FDA letter requests an evaluation of worst case rather than a prescribed calculation model, and the two should not be conflated.
For completeness, and to avoid conflating two separate public records: MediNatura separately conducted voluntary recalls on 10 and 16 December 2025 covering ReBoost Nasal Spray and ClearLife Allergy Nasal Spray for microbial contamination above specification. The warning letter does not cite those recalls and does not attribute them to the cleaning findings summarised here.
Sources
- US FDA, Warning Letter 320-26-27, Medinatura New Mexico, Inc., 716025, issued 10 December 2025 (primary source).
- Full letter text as issued, republished by EIN Presswire, 23 December 2025 (independent second copy used to cross-check every quotation above).
- US FDA, Process Validation: General Principles and Practices (guidance, 2011) — cited within the letter.
- US FDA recall notices for ReBoost and ClearLife nasal sprays, 10 and 16 December 2025 (separate matter, listed for context only).
Validation takeaway
A cleaning validation describes an equipment train and a product set at a point in time; the plant keeps changing after that point. In this letter the firm itself stated the study was not reflective of current operations after continued purchases of new equipment and additions of new products, and FDA's remedy targeted the process that should have caught this — change control and lifecycle management of equipment cleaning — alongside a retrospective assessment and a renewed worst-case evaluation. The instructive part is how ordinary the drift looks: each addition is locally reasonable, and nothing looks wrong until someone asks whether the study still covers what the plant makes.
Questions worth asking in our own programme
- For each non-dedicated equipment item, is there a current list of the products it carries, and does the cleaning validation cover that list as it stands today — not as it stood when the study was approved?
- When we buy equipment or add a product, which document forces the question 'does this change our validated cleaning state?', and does QA sign that decision before the item enters production?
- Could we reconstruct, from records, which product ran before which on each shared item during the last campaign window? If not, what would an investigation actually be able to scope?
- Does our periodic review of cleaning re-test the worst-case selection after products and equipment change, or does it mainly confirm that existing procedures were followed?
- Are maximum hold times before cleaning defined against the equipment train and product mix we run now?
- Where our records show a new product or equipment item added since the last cleaning study, is there a written, dated technical rationale for why the study still applies?
